Emilie’s Story – Preparing the best possible clinical and economic value proposition for your drug reimbursement file
Find out how you can adapt advisory board meetings to the dynamic needs of pharmaceutical market access today. Reinvent your follow-up and re-engage your advisors.
Download the Case Study for more information & ideas. Complete the form to your right.
Evaluating Current Barriers to Market Access in Canada
This survey was conducted September 2016 featuring responses from key market access professionals from across Canada and other pharma-industry stakeholders.
- Managing Costs
- Patient Advocacy
- Government Incentives
- Communication with Provincial Government
Bonus: This report also highlights additional suggestions and responses by survey respondents.
Get the detailed survey results by completing the form to your right.
Innomar – Dealing with the Expensive Shock of a Rare Disease
A recent CORD survey found that the median time to have a rare disease diagnosed is three to six years. If you are lucky enough to have a treatment for your condition, you may find yourself in sticker shock. Prescription drugs for rare diseases can cost in excess of hundreds of thousands of dollars or more per patient per year. In the same survey, over 70 percent of the patients indicated they had to incur personal costs for their treatment.
Fill out the form to read the entire report from Innomar.
Breaking through Silos
Read a Telus Health industry discussion paper to understand why bridging drug costs, health benefits and primary care is essential for Canada’s health.
Fill out the form to read the discussion.